1	State of Arkansas	A D:11		
2	93rd General Assembly	A Bill		
3	Regular Session, 2021		HOUSE BILL 1881	
4				
5	By: Representatives M. Gray, Wardlaw, Murdock, V. Flowers			
6	By: Senator Rapert			
7				
8		For An Act To Be Entitled		
9	AN ACT TO ESTABLISH THE 340B DRUG PRICING			
10	NONDISCRIMINATION ACT; AND FOR OTHER PURPOSES.			
11				
12		~		
13		Subtitle		
14	TO ESTA	BLISH THE 340B DRUG PRICING		
15	NONDISC	RIMINATION ACT.		
16				
17				
18	BE IT ENACTED BY THE GENI	ERAL ASSEMBLY OF THE STATE OF	F ARKANSAS:	
19				
20	SECTION 1. Arkansas Code Title 23, Chapter 92, is amended to add an			
21	additional subchapter to	read as follows:		
22				
23	<u>Subchapter 6</u>	- 340B Drug Pricing Nondiscr	<u>rimination Act</u>	
24				
25	23-92-601. Title.			
26	This subchapter shall be known and may be cited as the "340B Drug			
27	Pricing Nondiscrimination	n Act".		
28				
29	23-92-602. Definit	tions.		
30	As used in this sul	_		
31	(1) "Patient	t" means an individual seekir	ng medical diagnosis and	
32	<pre>treatment;</pre>			
33		cy" means the same as defined		
34		er" means a licensed pharmaci	ist as defined in § 17-	
35	<u>92-101;</u>			
36	<u>(4) "Third </u>	party" means:		

1	(A) A payor or the payor's intermediary; or		
2	(B) A pharmacy benefits manager; and		
3	(5) "340B drug pricing" means the program established under		
4	section 602 of the Veterans Health Care Act of 1992, Pub. L. No. 102-585.		
5			
6	23-92-603. Third-party requirements.		
7	A third party shall:		
8	(1) Inform a patient that the patient is not required to use a		
9	mail-order pharmacy;		
10	(2) Obtain a signed waiver from a patient before allowing the		
11	use of a mail-order pharmacy;		
12	(3) Make drug formulary and coverage decisions based on the		
13	third party's normal course of business;		
14	(4) Allow a patient the freedom to use any pharmacy or any		
15	provider the patient chooses, whether or not the pharmacy participates in		
16	340B drug pricing; and		
17	(5) Eliminate discriminatory contracting as it relates to:		
18	(A) Transferring the benefit of 340B drug-pricing savings		
19	from one (1) entity, including critical access hospitals, federally qualifie		
20	health centers, other hospitals, or 340B drug-pricing participants and their		
21	underserved patients, to another entity, including without limitation		
22	pharmacy benefits managers, private insurers, and managed care organizations;		
23	(B) Pricing that occurs when offering a lower		
24	reimbursement for a drug purchased under 340B drug pricing than for the same		
25	drug not purchased under 340B drug pricing;		
26	(C) Refusal to cover drugs purchased under 340B drug		
27	<pre>pricing;</pre>		
28	(D) Refusal to allow 340B drug-pricing pharmacies to		
29	participate in networks; and		
30	(E) Charging more than fair market value or seeking profit		
31	sharing in exchange for services involving 340B drug pricing.		
32			
33	23-92-604. Third party - Pharmaceutical manufacturer - Prohibitions.		
34	(a) A third party shall not:		
35	(1) Coerce a patient into using a mail-order pharmacy;		
36	(2) Require a patient to use a mail-order pharmacy;		

1	(3) Pay 3406 drug pricing to a pharmacy that participates in the		
2	340B drug pricing that is less than what a third party pays to any other		
3	pharmacy for the same product and quantity dispensed, including ingredient		
4	costs and other fees, reimbursements, adjustments, or recoupments applied to		
5	a pharmacy by a third party;		
6	(4) Discriminate or impose any separate terms upon a pharmacy on		
7	the basis that a pharmacy participates in 340B drug pricing;		
8	(5) Require a pharmacy to reverse, resubmit, or clarify a 340B		
9	drug-pricing claim after the initial adjudication unless these actions are in		
10	the normal course of pharmacy business and not related to 340B drug pricing;		
11	(6) Require a billing modifier to indicate that the drug or		
12	claim is a 340B drug-pricing claim unless the drug or claim is being billed		
13	to the fee-for-service Arkansas Medicaid Program;		
14	(7) Modify a patient's copayment on the basis of a pharmacy's		
15	participation in 340B drug pricing;		
16	(8) Exclude a pharmacy from a network on the basis of the		
17	pharmacy's participation in 340B drug pricing;		
18	(9) Establish or set network adequacy requirements based on 340B		
19	drug pricing participation by a provider or a pharmacy; or		
20	(10) Prohibit an entity authorized to participate in 340B drug		
21	pricing or a pharmacy under contract with an entity authorized to participate		
22	in 340B drug pricing from participating in the third party's provider		
23	network.		
24	(b) A third party that is a pharmacy benefits manager shall not base		
25	the drug formulary or drug coverage decisions upon the 340B drug-pricing		
26	status of a drug, including price or availability, or whether a dispensing		
27	pharmacy participates in 340B drug pricing.		
28	(c) A pharmaceutical manufacturer shall not:		
29	(1) Prohibit a pharmacy from contracting or participating with		
30	an entity authorized to participate in 340B drug pricing by denying access to		
31	drugs that are manufactured by the pharmaceutical manufacturer; or		
32	(2) Deny or prohibit 340B drug pricing for an Arkansas-based		
33	community pharmacy that receives drugs purchased under a 340B drug pricing		
34	contract pharmacy arrangement with an entity authorized to participate in		
35	340B drug pricing.		

1	23-92-605. Pharmacy claims.		
2	All pharmacy claims processed by a pharmacy that participates in 340B		
3	drug pricing are final at the point of adjudication.		
4			
5	23-92-606. Rules.		
6	The Insurance Commissioner shall promulgate rules to implement this		
7	subchapter.		
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			